Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
50 hedge funds and large institutions have $63.3M invested in Cidara Therapeutics in 2019 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 8 closing their positions.
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
119% more capital invested
Capital invested by funds: $28.9M → $63.3M (+$34.4M)
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
28% more funds holding
Funds holding: 39 → 50 (+11)
0.21% less ownership
Funds ownership: 2.7% → 2.5% (-0.21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$410K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$392K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$331K |
| 4 |
Renaissance Technologies
New York
|
+$275K |
| 5 |
Millennium Management
New York
|
+$217K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$319K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$199K |
| 3 |
Goldman Sachs
New York
|
-$41.8K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$38K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$14.7K |
CDTX Hedge Fund Activity: Q4 2019 in Review
50 of the 5,091 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q4 2019, worth a combined $63.3M — up 119% from $28.9M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new CDTX positions and 8 closed out — a net gain of 12 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $410K. The largest seller was BlackRock, cutting an estimated $319K.
- 50 institutional investors held Cidara Therapeutics (CDTX) as of Q4 2019, up from 39 in Q3 2019.
- Funds reported $63.3M of Cidara Therapeutics stock for Q4 2019, up 119% quarter-over-quarter.
- 20 funds opened new Cidara Therapeutics positions in Q4 2019 and 8 closed out, a net change of +12 holders.
- The largest Cidara Therapeutics buyer in Q4 2019 was Bank of Montreal, an estimated $410K added.
- The largest Cidara Therapeutics seller in Q4 2019 was BlackRock, an estimated $319K sold.
Based on aggregated 13F filings for Q4 2019.